DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Exisulind is an investigational drug.
There have been 12 clinical trials for Exisulind. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2001.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are National Cancer Institute (NCI), OSI Pharmaceuticals, and Alliance for Clinical Trials in Oncology.
Recent Clinical Trials for Exisulind
|Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer||National Cancer Institute (NCI)||Phase 2|
|Exisulind Versus Placebo After Surgical Removal of the Prostate||OSI Pharmaceuticals||Phase 2|
|Exisulind Versus Placebo After Surgical Removal of the Prostate||Mayo Clinic||Phase 2|